Form 4: VolitionRx GC Awarded 24,031 RSUs

VolitionRx's General Counsel, Nicholas Plummer, was awarded 24,031 restricted stock units as part of his compensation, vesting through early 2026.

Summary

• Nicholas Plummer, General Counsel of Volition Diagnostics, received an award of 24,031 restricted stock units (RSUs) of VolitionRx Ltd. common stock.
• The RSUs were awarded on August 15, 2025, in lieu of cash compensation.
• The RSUs will be earned in six approximately equal monthly installments commencing September 1, 2025.
• Further vesting occurs in two installments: 12,016 units on November 1, 2025, and 12,015 units on February 1, 2026.
• Vesting is contingent on continued service by the reporting person throughout each applicable earning and vesting date.
• Upon vesting and settlement, the reporting person will receive shares of common stock equal to the number of earned and vested RSUs.
• Following this award, Nicholas Plummer beneficially owns 207,877 shares of common stock.

Sentiment

Score: 7

Explanation: The award of RSUs to an executive is generally positive as it aligns interests and conserves cash, though it implies future dilution. This is a routine compensation event.

Positives

• The award of restricted stock units aligns management's long-term interests with those of shareholders.
• Utilizing RSUs in lieu of cash compensation helps conserve the company's cash reserves.

Negatives

• The transaction does not provide immediate cash inflow for the company.
• Potential future dilution of existing shares will occur upon the vesting and settlement of the RSUs into common stock.

Risks

• Vesting of the restricted stock units is subject to the reporting person's continued service, meaning the award could be forfeited if employment ceases before vesting dates.
• Future dilution of existing shares will occur when the RSUs vest and are settled into common stock.

Future Outlook

The restricted stock units are scheduled to be earned in six approximately equal monthly installments commencing September 1, 2025, with additional time-based vesting installments on November 1, 2025, and February 1, 2026, contingent on continued service.

Management Comments

• Nicholas Plummer, General Counsel of Volition Diagnostics, was awarded 24,031 restricted stock units in lieu of cash compensation under the Issuer's 2015 Stock Incentive Plan.

Industry Context

The award of restricted stock units (RSUs) to an executive in lieu of cash compensation is a common practice in the biotechnology and diagnostics industry, aligning executive incentives with long-term shareholder value and conserving cash for research and development or operational expenses.

Comparison to Industry Standards

• The use of equity-based compensation like RSUs is a standard practice across various industries, including biotech, to attract, retain, and incentivize key personnel.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) also frequently utilize similar equity compensation structures for their executives to align interests with company performance and shareholder returns.

Stakeholder Impact

• Shareholders: Potential future dilution from RSU conversion, but also improved alignment of executive incentives with long-term company performance.
• Employees: Demonstrates a commitment to equity-based compensation for key personnel, which can aid in retention and motivation.

Next Steps

• RSUs to be earned in six approximately equal monthly installments commencing September 1, 2025.
• First time-based vesting installment of 12,016 units on November 1, 2025.
• Second time-based vesting installment of 12,015 units on February 1, 2026.

Key Dates

Recommendation

This Form 4 reports a routine equity compensation award to an executive, which is a common practice to align interests. It does not present new information that would significantly alter the investment thesis for VolitionRx, thus a 'hold' recommendation is appropriate.

Keywords

VolitionRx, VNRX, Restricted Stock Units, RSU, Insider Transaction, SEC Form 4, Executive Compensation, Stock Award, Nicholas Plummer